Sonja Schrepfer, MD, PhD, Sana Biotechnology, Seattle, WA, shares her highlights from the American Society for Cell & Gene Therapy (ASGCT) 24th Annual Meeting 2021. Recent developments include an improved focus and understanding of immunological barriers associated with allogeneic induced pluripotent stem cells (iPSCs) and chimeric antigen receptor (CAR) T-cells. Other highlights include advances seen in the development of iPSC-based therapies including iPSC-derived dopaminergic neurons for Parkinson’s disease and iPSC-derived retinal pigment epithelium (RPE) for macular degeneration. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.
Sonja Schrepfer is a scientific founder and stockholder of Sana Biotechnology, Inc. (“Sana”). Since Feb 2019, Sonja Schrepfer has been an employee of Sana in South San Francisco, CA, and since 2015, has been a Professor of Surgery at the University of California San Francisco (“UCSF”).